Sodium glucose co-transporter 2 inhibition: a new avenue to protect the kidney

Por Heerspink, Hiddo J L
Publicado no Nephrol Dial Transplant (2019)

Trial Design Innovations to Accelerate Therapeutic Advances in Chronic Kidney Disease: Moving from Single Trials to an Ongoing Platform

Por Heerspink, Hiddo J.L., Perkovic, Vlado
Publicado no Clin J Am Soc Nephrol (2018)

Novel anti-inflammatory drugs for the treatment of diabetic kidney disease

Por Heerspink, Hiddo J. L., De Zeeuw, Dick
Publicado no Diabetologia (2016)

Treating diabetic complications; from large randomized clinical trials to precision medicine

Por Heerspink, Hiddo J. L., de Zeeuw, Dick
Publicado no Diabetes Obes Metab (2018)

Time for clinical decision support systems tailoring individual patient therapy to improve renal and cardiovascular outcomes in diabetes and nephropathy

Por de Zeeuw, Dick, Heerspink, Hiddo J L
Publicado no Nephrol Dial Transplant (2020)

New clinical trial designs for establishing drug efficacy and safety in a precision medicine era

Por Heerspink, Hiddo J. L., List, James, Perkovic, Vlado
Publicado no Diabetes Obes Metab (2018)

Editorial: The role of sodium-glucose cotransporter 2 inhibitors in the management of chronic kidney disease

Por Heerspink, Hiddo J L, Fouque, Denis, Wanner, Christoph
Publicado no Nephrol Dial Transplant (2020)

Proteomics for prediction of disease progression and response to therapy in diabetic kidney disease

Por Pena, Michelle J., Mischak, Harald, Heerspink, Hiddo J. L.
Publicado no Diabetologia (2016)

ACCORDION: Ensuring That We Hear the Music Clearly

Por Wong, Muh Geot, Heerspink, Hiddo J.L., Perkovic, Vlado
Publicado no Clin J Am Soc Nephrol (2018)

Exposure–response relationships of dapagliflozin on cardiorenal risk markers and adverse events: A pooled analysis of 13 phase II/III trials

Por Koomen, Jeroen V., Stevens, Jasper, Heerspink, Hiddo J.L.
Publicado no Br J Clin Pharmacol (2020)

New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors

Por Dekkers, Claire C. J., Gansevoort, Ron T., Heerspink, Hiddo J. L.
Publicado no Curr Diab Rep (2018)

Multimarker Panels in Diabetic Kidney Disease: The Way to Improved Clinical Trial Design and Clinical Practice?

Por Perco, Paul, Pena, Michelle, Heerspink, Hiddo J.L., Mayer, Gert
Publicado no Kidney Int Rep (2018)

Effects of sodium glucose cotransporter 2 inhibitors on mineral metabolism in type 2 diabetes mellitus

Por Vinke, Joanna Sophia J., Heerspink, Hiddo J.L., de Borst, Martin H.
Publicado no Curr Opin Nephrol Hypertens (2019)

No significant association of type 2 diabetes‐related genetic risk scores with glycated haemoglobin levels after initiating metformin or sulphonylurea derivatives

Por Martono, Doti P., Heerspink, Hiddo J.L., Hak, Eelko, Denig, Petra, Wilffert, Bob
Publicado no Diabetes Obes Metab (2019)

Blood pressure‐lowering effects of sulodexide depend on albuminuria severity: post hoc analysis of the sulodexide microalbuminuria and macroalbuminuria studies

Por Olde Engberink, Rik H. G., Heerspink, Hiddo J. L., de Zeeuw, Dick, Vogt, Liffert
Publicado no Br J Clin Pharmacol (2016)

Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects

Por Heerspink, Hiddo J. L., Desai, Mehul, Jardine, Meg, Balis, Dainius, Meininger, Gary, Perkovic, Vlado
Publicado no J Am Soc Nephrol (2017)

Is Chronic Dialysis the Right Hard Renal End Point To Evaluate Renoprotective Drug Effects?

Por Weldegiorgis, Misghina, de Zeeuw, Dick, Dwyer, Jamie P., Mol, Peter, Heerspink, Hiddo J.L.
Publicado no Clin J Am Soc Nephrol (2017)

Precision medicine in diabetes and diabetic kidney disease: Regulatory considerations

Por Mol, Peter G. M., Thompson, Aliza, Heerspink, Hiddo J. L., Leufkens, Hubert G. M.
Publicado no Diabetes Obes Metab (2018)

Association between individual cholesterol and proteinuria response and exposure to atorvastatin or rosuvastatin

Por Kroonen, Marjolein Y. A. M., Stevens, Jasper, de Zeeuw, Dick, Heerspink, Hiddo J. L.
Publicado no Diabetes Obes Metab (2019)

A novel drug response score more accurately predicts renoprotective drug effects than existing renal risk scores

Por Idzerda, Nienke M. A., Tye, Sok Cin, de Zeeuw, Dick, Heerspink, Hiddo J. L.
Publicado no Ther Adv Endocrinol Metab (2021)